A study investigated the combination of interferon-alpha2 (IFN), azacitidine (Aza), and ruxolitinib for treating accelerated-phase (AP) and blast-phase (BP) MPN [153]. This evidence concerns the gene IFNA1 and myeloproliferative neoplasm.